Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Baxter
Colorcon
Harvard Business School
McKinsey

Last Updated: September 26, 2022

Details for Patent: 7,268,156


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,268,156 protect, and when does it expire?

Patent 7,268,156 protects COREG CR and is included in one NDA.

Protection for COREG CR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-seven patent family members in fourteen countries.

Summary for Patent: 7,268,156
Title:Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
Abstract:The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat hypertension, congestive heart failure and angina, etc.
Inventor(s): Brook; Christopher S. (King of Prussia, PA), Chen; Wei (Woodbury, MN), Spoors; Paul G. (King of Prussia, PA)
Assignee: SB Pharmco Puerto Rico Inc. (Hato Rey, PR)
Application Number:10/518,654
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,268,156

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Woodward COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-001 Oct 20, 2006 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Woodward COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-002 Oct 20, 2006 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Woodward COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-003 Oct 20, 2006 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Woodward COREG CR carvedilol phosphate CAPSULE, EXTENDED RELEASE;ORAL 022012-004 Oct 20, 2006 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,268,156

PCT Information
PCT FiledJune 27, 2003PCT Application Number:PCT/US03/20408
PCT Publication Date:January 08, 2004PCT Publication Number: WO20/04/002419

International Family Members for US Patent 7,268,156

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003248746 See Plans and Pricing
Brazil 0312102 See Plans and Pricing
Canada 2492060 See Plans and Pricing
China 101898995 See Plans and Pricing
China 103254114 See Plans and Pricing
China 103288714 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Boehringer Ingelheim
AstraZeneca
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.